WO2001085151A3 - Traitement du psoriasis - Google Patents

Traitement du psoriasis Download PDF

Info

Publication number
WO2001085151A3
WO2001085151A3 PCT/US2001/014988 US0114988W WO0185151A3 WO 2001085151 A3 WO2001085151 A3 WO 2001085151A3 US 0114988 W US0114988 W US 0114988W WO 0185151 A3 WO0185151 A3 WO 0185151A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
treatment
animal model
chimeric animal
chimeric
Prior art date
Application number
PCT/US2001/014988
Other languages
English (en)
Other versions
WO2001085151A2 (fr
Inventor
Eugene M Farber
Siba P Raychaudhuri
Smriti K Raychaudhuri
Original Assignee
Psoriasis Res Inst
Eugene M Farber
Siba P Raychaudhuri
Smriti K Raychaudhuri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psoriasis Res Inst, Eugene M Farber, Siba P Raychaudhuri, Smriti K Raychaudhuri filed Critical Psoriasis Res Inst
Priority to AU2001261324A priority Critical patent/AU2001261324A1/en
Publication of WO2001085151A2 publication Critical patent/WO2001085151A2/fr
Publication of WO2001085151A3 publication Critical patent/WO2001085151A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Environmental Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne le traitement du psoriasis par un inhibiteur du facteur de croissance du tissu nerveux, une composition comprenant un inhibiteur du facteur de croissance du tissu nerveux, un modèle animal du psoriasis, et un procédé de criblage des composants pour le traitement du psoriasis.
PCT/US2001/014988 2000-05-08 2001-05-08 Traitement du psoriasis WO2001085151A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001261324A AU2001261324A1 (en) 2000-05-08 2001-05-08 Psoriasis treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56657400A 2000-05-08 2000-05-08
US09/566,574 2000-05-08

Publications (2)

Publication Number Publication Date
WO2001085151A2 WO2001085151A2 (fr) 2001-11-15
WO2001085151A3 true WO2001085151A3 (fr) 2002-05-23

Family

ID=24263461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014988 WO2001085151A2 (fr) 2000-05-08 2001-05-08 Traitement du psoriasis

Country Status (2)

Country Link
AU (1) AU2001261324A1 (fr)
WO (1) WO2001085151A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623994B1 (ko) 2015-12-22 2024-01-11 장-노엘 또렐 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023832D1 (de) 2003-05-16 2009-12-10 Univ Laval Cns chlorid-modulierung und verwendung derselben
EP1653972A1 (fr) * 2003-07-23 2006-05-10 Creabilis Therapeutics s.r.l. Utilisation topique d'inhibiteurs de tyrosine kinase d'origine microbienne dans la prevention et le traitement de troubles cutanes se caracterisant par une proliferation cellulaire excessive
WO2005110490A1 (fr) 2004-05-14 2005-11-24 Universite Laval Modulation de la phospholipase c gamma et ses utilisations pour la gestion de la douleur et de la nociception
MX2008002524A (es) * 2005-08-25 2008-03-14 Creabilis Therapeutics Spa Conjugados polimericos de k-252a y sus derivados.
ES2352929B1 (es) * 2009-08-14 2012-01-26 Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) Modelo humanizado de psoriasis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038093A1 (fr) * 1996-04-05 1997-10-16 Brigham & Women's Hospital, Inc. Modele pour psoriasis
WO1997049406A1 (fr) * 1996-06-25 1997-12-31 Cephalon, Inc. Utilisation du derive de k-252a dans le traitement de troubles du systeme nerveux peripherique ou central, et de l'hyperproduction de cytokines
WO1998044908A1 (fr) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Procede de regulation de la croissance epitheliale
WO2000001699A1 (fr) * 1998-07-02 2000-01-13 Bayer Aktiengesellschaft Derives d'indolocarbazole utiles pour le traitement de troubles de neurodegenerescence et du cancer
WO2000016756A2 (fr) * 1998-09-24 2000-03-30 Innovet Italia S.R.L. Derives de n-acylvanillinamide capables d'activer des recepteurs peripheriques de cannabinoides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038093A1 (fr) * 1996-04-05 1997-10-16 Brigham & Women's Hospital, Inc. Modele pour psoriasis
WO1997049406A1 (fr) * 1996-06-25 1997-12-31 Cephalon, Inc. Utilisation du derive de k-252a dans le traitement de troubles du systeme nerveux peripherique ou central, et de l'hyperproduction de cytokines
WO1998044908A1 (fr) * 1997-04-07 1998-10-15 The Board Of Trustees Of The Leland Stanford Junior University Procede de regulation de la croissance epitheliale
WO2000001699A1 (fr) * 1998-07-02 2000-01-13 Bayer Aktiengesellschaft Derives d'indolocarbazole utiles pour le traitement de troubles de neurodegenerescence et du cancer
WO2000016756A2 (fr) * 1998-09-24 2000-03-30 Innovet Italia S.R.L. Derives de n-acylvanillinamide capables d'activer des recepteurs peripheriques de cannabinoides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAM T ET AL: "Pharmacological modulation of induction and treatment of psoriasis using human skin grafts transplanted onto SCID mice", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, no. 4, 1997, pages 572, XP001041554 *
PINCELLI C ET AL: "Autocrine nerve growth factor in human keratinocytes", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 22, no. 2, February 1999 (1999-02-01), pages 71 - 79, XP001041596 *
PINCELLI C: "Nerve growth factor and keratinocytes: a role in psoriasis.", EUR J DERMATOL, vol. 10, no. 2, March 2000 (2000-03-01), pages 85 - 90, XP002184137 *
RAYCHAUDHURI S ET AL: "Role of neuroimmunologic inflammation in psoriasis in a SCID mouse-human skin animal model", FASEB J, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1247, XP002184136 *
YAMAMOTO T ET AL: "Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 17, no. 1, May 1998 (1998-05-01), pages 8 - 14, XP001041546 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623994B1 (ko) 2015-12-22 2024-01-11 장-노엘 또렐 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물

Also Published As

Publication number Publication date
WO2001085151A2 (fr) 2001-11-15
AU2001261324A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
WO2002012190A3 (fr) Aryloxypiperidines non-imidazole
MX274785B (es) Metodo para controlar plagas de insectos particulares aplicando compuestos de antranilamida.
AU2003267514A1 (en) Method for making nitrile compounds from ethylenically unsaturated compounds
ZA200106683B (en) Method for the preparation of citalopram.
HK1054378A1 (en) Method for the preparation of citalopram.
MXPA03008630A (es) Derivados de arilisoxazolinas, procedimientos para su preparacion y su utilizacion como agentes plaguicidas.
AU2003297197A1 (en) Method for increasing the efficacy of agricultural chemicals
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
MXPA03001800A (es) Proceso para la preparacion de fenilacetonitrilos sustituidos.
WO2001085151A3 (fr) Traitement du psoriasis
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
WO2003002521A3 (fr) Procede de preparation de composes type azoique
ZA200303189B (en) Method for producing a piece of timber including heartwood.
ZA200106158B (en) Method for production of catalyst.
WO2002085915A3 (fr) Azoles a effet insecticide
ZA200106159B (en) Method for production of catalyst.
ZA200104999B (en) Method for the production of formaldehyde.
NO20041437L (no) Fremgangsmate for forbedring av jord ved bio-eksplosjon og tilveiebringelse av mikroorganismer for dette.
NO20050769L (no) Fremgangsmate til a innfore en 1,2-dobbelbinding i 3-okso-4-azasteroidforbindelser
WO2003070696A3 (fr) Arylcetones substituees
WO1999046263A3 (fr) Benzoheterocyclyloximes fongicides
AU2003288255A8 (en) Method for producing transgenic plants having an elevated vitamin E content by modifying the serine-acetyltransferase content
AU2001262470A1 (en) Method for treating plant material, compositions comprising n-acylglucosamine derivatives, use of said compounds
IL150654A0 (en) A METHOD FOR THE ISOLATION OF 6alpha,9alpha-DIFLUORO-11beta,17alpha-DIHYDROXY-16alpha-METHYLPREGNA-3-OXO-1,4-DIENE-17beta-CARBOXYLIC ACID
WO2001039787A3 (fr) Amides d'acide glyoxylique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP